BMO Capital Markets raised its 12-month price target on DuPont (NYSE:DD) to $60.00 from $50.00 on Thursday and maintained an Outperform rating on the chemicals companys stock. At the time of the update, DuPont shares were trading at $51.53, with a reported price-to-earnings ratio of 368.13.
According to InvestingPro data cited in the update, the stock is trading close to its Fair Value after returning 73.07% over the prior six months. BMOs note emphasized DuPonts exposure to secular growth themes in water and healthcare - areas that together make up roughly half of the companys business - as key rationale for forecasts of double-digit earnings-per-share growth.
The research firm also pointed to recent analyst behavior as supportive of its outlook. InvestingPro data show five analysts have revised earnings estimates upward for the upcoming period, which BMO referenced in framing a more optimistic EPS trajectory for DuPont.
Dividend continuity and yield were highlighted as relevant income metrics for investors. DuPont has maintained dividend distributions for 55 consecutive years and currently offers a yield of 1.55%.
BMO noted additional upside potential from operational and market dynamics. Specifically, the firm suggested profit improvement in DuPonts Diversified segment could emerge as the construction market appears to be near cyclical lows, implying room for recovery in end-market demand. The research team also underscored significant financial flexibility on DuPonts balance sheet, suggesting that optionality could be employed for share repurchases or merger and acquisition activity.
Within BMOs coverage, DuPont remains designated a "Top Large-Cap Pick," with the firm indicating that modest multiple expansion could contribute to moving the stock toward the new $60 target.
Recent company results fed into broader analyst activity. DuPont de Nemours Inc. reported fourth-quarter 2025 earnings that exceeded consensus forecasts, delivering EPS of $0.46 versus an expected $0.43, and reporting revenue of $1.7 billion compared with a projection of $1.69 billion.
Following the quarterly report, other firms adjusted their targets. RBC Capital raised its price target on DuPont to $161 from $150 while retaining an Outperform rating. KeyBanc increased its target to $57 from $51 and kept an Overweight rating; KeyBanc analyst Aleksey Yefremov cited greater confidence in DuPonts long-term growth algorithm after the companys portfolio reshaping post-Qnity divestiture.
These analyst updates and the companys most recent results illustrate the set of factors market participants are weighing: end-market exposure to water and healthcare, a near-term recovery opportunity in construction-driven segments, a long-standing dividend record, recent positive earnings revisions, and balance-sheet optionality that could be deployed to support shareholder returns.
Bottom line - BMOs move to a $60 target reflects conviction in secular growth end markets and potential margin recovery opportunities, while other firms have similarly nudged their targets higher after DuPonts favorable quarter. The stocks high reported P/E and reliance on multiple expansion are among the valuation considerations embedded in analyst views.